ian

About Ian Maurer

This author has not yet filled in any details.
So far Ian Maurer has created 20 entries.

Pathline Emerge Launches DNA Profiling Tests using GenomOncology’s GO Clinical Workbench

July 12, 2016

CLEVELAND – GenomOncology today announced that Pathline Emerge recently went live with the GO Clinical Workbench for rapid analysis and reporting of their next-generation sequencing tests.

“Pathline Emerge takes a multi-disciplinary approach to evaluate specific types of cancer to support personalized medicine. Our full-service pathology laboratory was one of the first to obtain […]

July 12th, 2016|News & Events|Comments Off on Pathline Emerge Launches DNA Profiling Tests using GenomOncology’s GO Clinical Workbench

Congenica and GenomOncology announce collaborative agreement at AMP

November 5, 2015

CAMBRIDGE UK and CLEVELAND USA – Congenica, leader in genomic interpretation and diagnostics in rare genetic disease, and GenomOncology, specialists in precision medicine technology in the field of oncology, are announcing a pilot collaboration that will support the commercialisation of each other’s products in the USA and UK respectively and offer strategic […]

November 5th, 2015|News & Events|Comments Off on Congenica and GenomOncology announce collaborative agreement at AMP

ArcherDX and GenomOncology to Collaborate on NGS Workflow Applications

November 3, 2015

BOULDER, CO -(Business Week)– ArcherDX, Inc., the leader in NGS-based gene fusion detection, has announced an agreement with GenomOncology, Inc., the leader in NGS variant interpretation, to co-market Archer’s NGS assays and GenomOncology’s data interpretation software for somatic mutation detection and reporting. Under terms of the agreement, GenomOncology’s GO Clinical Workbench™ will […]

November 3rd, 2015|News & Events|Comments Off on ArcherDX and GenomOncology to Collaborate on NGS Workflow Applications

GenomOncology appoints David Lasecki as Chief Commercialization Officer

October 29, 2015

CLEVELAND – GenomOncology announced today that David Lasecki has joined the company as Chief Commercialization Officer. In this position, Mr. Lasecki will lead the company’s growth strategy by working with key stakeholders in the healthcare industry to promote the widespread adoption of precision medicine.

Mr. Lasecki has more than 16 years of molecular […]

October 29th, 2015|News & Events|Comments Off on GenomOncology appoints David Lasecki as Chief Commercialization Officer

UCLA Health Implements Tumor DNA Profiling using GenomOncology’s GO Clinical Workbench

October 13, 2015

CLEVELAND – GenomOncology today announced that UCLA Health has adopted the GO Clinical WorkbenchTM to accelerate analysis and reporting for its tumor DNA profiling tests.

UCLA Health uses next generation sequencing for tumor profiling of its lung and colorectal cancer patients and has seen increasing demand for these treatment-guiding tests. Implementing and managing next […]

October 13th, 2015|News & Events|Comments Off on UCLA Health Implements Tumor DNA Profiling using GenomOncology’s GO Clinical Workbench

Hawai’i Pathologists’ Laboratory Launches First-in-Hawaii Tumor DNA Profiling Tests using GenomOncology’s GO Precision Medicine Portfolio

September 29, 2015

CLEVELAND and HONOLULU – GenomOncology and Hawai’i Pathologists’ Laboratory (HPL) today announced that HPL has launched the state’s first tumor DNA profiling tests based on next generation sequencing (NGS). HPL selected the GenomOncology team and its GO Precision Medicine PortfolioTM to drive their test validation, analysis, interpretation, and reporting processes.

HPL has launched […]

September 29th, 2015|News & Events|Comments Off on Hawai’i Pathologists’ Laboratory Launches First-in-Hawaii Tumor DNA Profiling Tests using GenomOncology’s GO Precision Medicine Portfolio

Thomas Jefferson University Hospital and GenomOncology Codeveloping Multi-assay Integrated Cancer Profiling System

September 18, 2015

CLEVELAND, OH – GenomOncology and Thomas Jefferson University Hospital announced today that they are co-developing an interpretation and reporting system for multi-assay cancer profiling. Jefferson expects to launch the system for testing acute myeloid leukemia (AML) in their molecular pathology laboratory this fall.

AML is recognized as a highly heterogeneous disease, and as […]

September 19th, 2015|News & Events|Comments Off on Thomas Jefferson University Hospital and GenomOncology Codeveloping Multi-assay Integrated Cancer Profiling System

GenomOncology appoints Vice President, New Products and Marketing

September 1, 2015

CLEVELAND, OH – GenomOncology announced today (September 1, 2015) that Benjamin Salisbury, Ph.D., has joined the company as Vice President, New Products and Marketing. In this position, Dr. Salisbury will be responsible for GenomOncology’s corporate and product marketing and for bringing to market new products that build upon the company’s precision medicine […]

September 19th, 2015|News & Events|Comments Off on GenomOncology appoints Vice President, New Products and Marketing

GenomOncology adds new Vice President, Translational Medicine

June 8, 2015

CLEVELAND, OH – GenomOncology today announced that Condie Carmack, Ph.D., has joined the company as Vice President, Translational Medicine. In this position, Dr. Carmack will report to Manuel Glynias, President, and CEO and will have responsibility for GenomOncology’s products and services in oncology and their newest venture in constitutional medicine. Dr. Carmack […]

September 19th, 2015|News & Events|Comments Off on GenomOncology adds new Vice President, Translational Medicine

Doctors look for genetic mutations to tailor therapies for cancer patients

June 5, 2015

CLEVELAND, OH (WOIO) – Matching the patient with the right kind of cancer fighting Dr. Alissa Marr and other physicians no longer tell patients with advanced lung cancer, “Here’s the chemotherapy that everyone with lung cancer gets.”

Today, the Omaha oncologist said, doctors often check to see if the person has a genetic […]

September 19th, 2015|News & Events|Comments Off on Doctors look for genetic mutations to tailor therapies for cancer patients